Literature DB >> 26191206

A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A/p16: a case report showing progression from a neurofibroma to a high-grade MPNST.

Shogo Tajima1, Kenji Koda2.   

Abstract

Development of malignant peripheral nerve sheath tumors (MPNSTs) is a stepwise process that involves the alteration of many cell cycle regulators and the double inactivation of the NF1 gene. Inactivation of the TP53 gene and deletion of the CDKN2A/p16 gene are known to play an important role in the process. Herein, we present a 19-year-old man with a familial history of neurofibromatosis type 1, in whom the tumor arose from the intercostal nerve and showed 3 components: a neurofibroma, a low-grade MPNST, and a high-grade MPNST. Loss of p16 expression and homozygous deletion of the CDKN2A/p16 gene were observed in both the low-grade and the high-grade MPNST. In contrast to low-grade MPNSTs, high-grade MPNSTs generally tend to lose expression of p16 and harbor homozygous deletion of the CDKN2A/p16 gene. Loss of p16 expression and homozygous deletion of the CDKN2A/p16 gene in low-grade MPNST in our case might be related to its progression to high-grade MPNST. To the best of our knowledge, this is the first study correlating the p16 expression status and CDKN2A/p16 gene alteration in low-grade MPNSTs.

Entities:  

Keywords:  CDKN2A/p16 gene; Malignant peripheral nerve sheath tumor; high grade; homozygous deletion; immunohistochemistry; low grade; neurofibromatosis type 1; p16

Mesh:

Substances:

Year:  2015        PMID: 26191206      PMCID: PMC4503078     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  15 in total

Review 1.  Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems.

Authors:  Fausto J Rodriguez; Andrew L Folpe; Caterina Giannini; Arie Perry
Journal:  Acta Neuropathol       Date:  2012-02-12       Impact factor: 17.088

2.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.

Authors:  G P Nielsen; A O Stemmer-Rachamimov; Y Ino; M B Moller; A E Rosenberg; D N Louis
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas.

Authors:  H P Kourea; C Cordon-Cardo; M Dudas; D Leung; J M Woodruff
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

4.  Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.

Authors:  Eline Beert; Hilde Brems; Bruno Daniëls; Ivo De Wever; Frank Van Calenbergh; Joseph Schoenaers; Maria Debiec-Rychter; Olivier Gevaert; Thomas De Raedt; Annick Van Den Bruel; Thomy de Ravel; Karen Cichowski; Lan Kluwe; Victor Mautner; Raf Sciot; Eric Legius
Journal:  Genes Chromosomes Cancer       Date:  2011-08-24       Impact factor: 5.006

5.  Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors.

Authors:  S Birindelli; F Perrone; M Oggionni; C Lavarino; B Pasini; B Vergani; G N Ranzani; M A Pierotti; S Pilotti
Journal:  Lab Invest       Date:  2001-06       Impact factor: 5.662

6.  Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.

Authors:  Gill Spurlock; Samantha J L Knight; Nick Thomas; Tim-Rasmus Kiehl; Abhijit Guha; Meena Upadhyaya
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-15       Impact factor: 4.553

Review 7.  Malignant Peripheral Nerve Sheath Tumor: molecular pathogenesis and current management considerations.

Authors:  Stephen R Grobmyer; John D Reith; Amir Shahlaee; Charles H Bush; Steven N Hochwald
Journal:  J Surg Oncol       Date:  2008-03-15       Impact factor: 3.454

8.  Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions.

Authors:  Holly Zhou; Cheryl M Coffin; Sherrie L Perkins; Sheryl R Tripp; Michael Liew; David H Viskochil
Journal:  Am J Surg Pathol       Date:  2003-10       Impact factor: 6.394

9.  Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms.

Authors:  Arie Perry; Sarah N Kunz; Christine E Fuller; Ruma Banerjee; Edith F Marley; Helen Liapis; Mark A Watson; David H Gutmann
Journal:  J Neuropathol Exp Neurol       Date:  2002-08       Impact factor: 3.685

10.  Molecular heterogeneity in malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1.

Authors:  Laura Thomas; Victor-Felix Mautner; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2012-09-04       Impact factor: 4.639

View more
  2 in total

1.  Mixed malignant peripheral nerve sheath tumor in the inguinal region: a case report.

Authors:  Mengyao Liu; Shuaichen Liu; Jinping Zhan; Weiyi Chen; Ping Yang; Huihui Zhou
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01

2.  The prognostic value of C-X-C motif chemokine receptor 4 in patients with sporadic malignant peripheral nerve sheath tumors.

Authors:  Chao Zhang; Fang-Yuan Chang; Wen-Ya Zhou; Ji-Long Yang
Journal:  Chin J Cancer       Date:  2017-10-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.